We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
MacroPore Biosurgery announced it has signed a definitive agreement to raise
$11 million from the sale of 1.1 million shares of common stock at $10.00 per
share.
Coapt Systems, developer of bioabsorbable implants for the fixation of soft
tissue in the plastic and reconstructive surgery markets, announced that it
has released the Endotine Midface Bone 4.5 for commercial sale in the U.S. market.
STAAR Surgical overhauled its executive management, replacing its chief financial
officer (CFO) and relieving Chief Executive David Bailey of his board chairmanship
duties.
Biomoda and Cytomyx, of Lexington, Mass., have entered into an agreement for
Cytomyx to provide human clinical samples to Biomoda for its diagnostic test
development program.
Baxa announced the release of the new PhaSeal System
Connector, which attaches a PhaSeal Injector to an IV line for safe administration
of hazardous drugs.
The FDA recommended that a confirmatory trial is necessary for Ortec International's
OrCel after reviewing clinical data that demonstrated clinical significance
in both the intent-to-treat population (all patients treated in the trial) as
well as those patients with ulcers for which use of OrCel is indicated (partial
and full thickness ulcers extending into dermis but not into the fascia).
Covalon Technologies, a medical biosystems company that has developed and patented
advanced therapeutic biomaterials for wound care and surgical applications and
coatings, announced that it has received FDA approval for its collagen scaffold
ColActive as a wound dressing.
Neurologix, a company engaged in the R&D of proprietary treatments for disorders
of the brain and central nervous system primarily utilizing gene therapies,
has entered into an agreement with Medtronic for the joint development, manufacturing
and commercialization of micro-infusion catheters designed to deliver gene therapy
into the brain and central nervous system.
Acacia Research announced that its CombiMatrix group has entered into a nonexclusive
distribution agreement with Inter Medical to distribute CombiMatrix's CustomArray
microarray products in Japan.
Talia Technology -- which develops and markets retinal imaging and diagnostic
equipment for screening, diagnosis and follow-up of common retinal diseases
-- expects to raise $19 million at a company value of $57 million, after money
on London's Alternative Investment Market (AIM).